Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The natural killer cytotoxicity pathway is the collection of molecular mechanisms by which natural killer (NK) cells identify and destroy abnormal cells, such as cancerous or infected cells. This involves multiple activating and inhibitory surface receptors on NK cells (e.g., natural cytotoxicity receptors, NKG2D, KIRs), complex signaling cascades (involving molecules like DAP10, DAP12, PI3K, Vav1, MAPK), immunological synapse formation, and subsequent exocytosis of cytotoxic granules containing perforin and granzymes leading to apoptosis of the target cell[1][3][4][5][7][8]. Additionally, death receptor pathways (such as Fas/FasL and TRAIL/TRAIL-R interactions) contribute to NK-mediated killing[1][8]. The "pathway" is not a discrete molecule but a regulated sequence of events across a network of interacting proteins. Key point: If you need information about a specific molecule in this pathway (e.g., NCR1 [NKp46], NKG2D, or CD16), you should specify that molecule or receptor. The term "Natural killer cytotoxicity pathway" itself is too broad for mapping to a single canonical target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cytotoxicity pathway.